Solventum SOLV
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Solventum (SOLV) Business Model and Operations Summary
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.
Key Insights
Solventum (SOLV) Core Market Data and Business Metrics
Latest Closing Price
$76.34Market Cap
$13.15 BillionPrice-Earnings Ratio
27.66Total Outstanding Shares
173 Million SharesTotal Employees
22,000Dividend
No dividendIPO Date
March 26, 2024SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
C/o 3m Company, St. Paul, MN, 55144-1000
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-240 Million |
| Net Cash Flow From Investing Activities, Continuing | $-380 Million |
| Net Cash Flow, Continuing | $565 Million |
| Net Cash Flow From Operating Activities | $1.19 Billion |
| Net Cash Flow From Investing Activities | $-380 Million |
| Net Cash Flow | $565 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Deferred | $-155 Million |
| Benefits Costs and Expenses | $7.65 Billion |
| Income/Loss From Continuing Operations Before Tax | $605 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $479 Million |
| Selling, General, and Administrative Expenses | $2.78 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $291 Million |
| Comprehensive Income/Loss | $291 Million |
| Other Comprehensive Income/Loss | $291 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-188 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $11.21 Billion |
| Long-term Debt | $8.01 Billion |
| Other Current Liabilities | $1.80 Billion |
| Other Non-current Assets | $7.04 Billion |
| Current Assets | $3.25 Billion |
| Assets | $14.46 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||